{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:57:09Z","timestamp":1757620629958,"version":"3.44.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13917-0","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:06:03Z","timestamp":1753988763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Ruiqiang","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingfei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7308-0009","authenticated-orcid":false,"given":"Yanbo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"13917_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho, A. M. et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int. J. Cancer. 156, 1336\u20131346 (2025).","journal-title":"Int. J. Cancer"},{"key":"13917_CR2","doi-asserted-by":"publisher","first-page":"1507501","DOI":"10.3389\/fimmu.2024.1507501","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer. Front. Immunol. 15, 1507501 (2024).","journal-title":"Front. Immunol."},{"key":"13917_CR3","doi-asserted-by":"crossref","unstructured":"Xu, S. & Lu, Z. The role of LMNB2 as a diagnostic and prognostic biomarker in lung adenocarcinoma. Asian J. Surg (2024).","DOI":"10.1016\/j.asjsur.2024.08.056"},{"key":"13917_CR4","doi-asserted-by":"crossref","unstructured":"Xu, S. & Lu, Z. Exploring FNDC4 as a biomarker for prognosis and immunotherapy response in lung adenocarcinoma. Asian J. Surg. (2024).","DOI":"10.1016\/j.asjsur.2024.09.054"},{"key":"13917_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","volume":"386","author":"M Pless","year":"2015","unstructured":"Pless, M. et al. Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 386, 1049\u20131056 (2015).","journal-title":"Lancet"},{"key":"13917_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","volume":"374","author":"KS Albain","year":"2009","unstructured":"Albain, K. S. et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 374, 379\u2013386 (2009).","journal-title":"Lancet"},{"key":"13917_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","volume":"23","author":"C Le Pechoux","year":"2022","unstructured":"Le Pechoux, C. et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol. 23, 104\u2013114 (2022).","journal-title":"Lancet Oncol."},{"key":"13917_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(21)00196-3","volume":"397","author":"R Rosell","year":"2021","unstructured":"Rosell, R. & Gonzalez-Cao, M. Cemiplimab monotherapy in advanced non-squamous and squamous NSCLC. Lancet. 397, 557\u2013559 (2021).","journal-title":"Lancet"},{"key":"13917_CR9","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.3390\/curroncol28050350","volume":"28","author":"X Chen","year":"2021","unstructured":"Chen, X. & Ma, K. Neoadjuvant therapy in lung cancer: what is most important: objective response rate or major pathological response? Curr. Oncol. 28, 4129\u20134138 (2021).","journal-title":"Curr. Oncol."},{"key":"13917_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/cncr.31105","volume":"124","author":"HI Assi","year":"2018","unstructured":"Assi, H. I. et al. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 124, 248\u2013261 (2018).","journal-title":"Cancer"},{"key":"13917_CR11","doi-asserted-by":"crossref","unstructured":"Huang, S. et al. Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma. Cancer Lett. 217272 (2024).","DOI":"10.1016\/j.canlet.2024.217272"},{"key":"13917_CR12","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986 (2018).","journal-title":"N. Engl. J. Med."},{"key":"13917_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2020.11.018","volume":"151","author":"EB Garon","year":"2021","unstructured":"Garon, E. B. et al. Pemetrexed maintenance with or without pembrolizumab in non-squamous NSCLC: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. Lung Cancer. 151, 25\u201329 (2021).","journal-title":"Lung Cancer"},{"key":"13917_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2020.11.018","volume":"151","author":"EB Garon","year":"2021","unstructured":"Garon, E. B., Kim, J. S. & Govindan, R. Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: a cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. Lung Cancer. 151, 25\u201329 (2021).","journal-title":"Lung Cancer"},{"key":"13917_CR15","first-page":"2416","volume":"29","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. & Wang, W. Efficacy of bevacizumab combined with PC chemotherapy in advanced NSCLC. Henan Med. Res. 29, 2416\u20132417 (2020).","journal-title":"Henan Med. Res."},{"key":"13917_CR16","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.7150\/jca.47072","volume":"11","author":"X Hao","year":"2020","unstructured":"Hao, X. et al. Nab-paclitaxel in combination with bevacizumab in patients with non-squamous NSCLC after failure of at least one prior systemic regimen. J. Cancer. 11, 6421\u20136428 (2020).","journal-title":"J. Cancer"},{"key":"13917_CR17","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","volume":"30","author":"E Jimenez Aguilar","year":"2019","unstructured":"Jimenez Aguilar, E. et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann. Oncol. 30, 1653\u20131659 (2019).","journal-title":"Ann. Oncol."},{"key":"13917_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0600-6","volume":"7","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. First-line treatment for patients with advanced non-small cell carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. J. Immunother. Cancer. 7, 1\u20136 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"13917_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer. 21, 28 (2022).","journal-title":"Mol. Cancer"},{"key":"13917_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","volume":"25","author":"H Hayashi","year":"2020","unstructured":"Hayashi, H. & Nakagawa, K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int. J. Clin. Oncol. 25, 818\u2013830 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"13917_CR21","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews, L. P., Yano, H. & Vignali, D. A. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat. Immunol. 20, 1425\u20131434 (2019).","journal-title":"Nat. Immunol."},{"key":"13917_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","volume":"29","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat. Med. 29, 593\u2013604 (2023).","journal-title":"Nat. Med."},{"issue":"15_suppl","key":"13917_CR23","doi-asserted-by":"publisher","first-page":"e21072","DOI":"10.1200\/JCO.2021.39.15_suppl.e21072","volume":"39","author":"B Han","year":"2021","unstructured":"Han, B. et al. Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 39 (15_suppl), e21072 (2021).","journal-title":"J. Clin. Oncol."},{"key":"13917_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae, Y. K. et al. Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer: lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J. Immunother. Cancer. 6, 1\u201327 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"13917_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.athoracsur.2024.10.007","volume":"120","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Outcomes after neoadjuvant therapy with or without immunotherapy followed by pneumonectomy in non-small cell lung cancer patients. Ann. Thorac. Surg. 120, 118\u2013128 (2024).","journal-title":"Ann. Thorac. Surg."},{"key":"13917_CR26","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.21037\/jtd-24-1923","volume":"17","author":"T Cheng","year":"2025","unstructured":"Cheng, T. et al. Pneumonectomy after neoadjuvant immunotherapy combined with chemotherapy is a safe and effective option for central non-small-cell lung cancer patients, a single-center experience. J. Thorac. Dis. 17, 3085 (2025).","journal-title":"J. Thorac. Dis."},{"key":"13917_CR27","doi-asserted-by":"publisher","first-page":"e21682","DOI":"10.1200\/JCO.2020.38.15_suppl.e21682","volume":"38","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC). J. Clin. Oncol. 38, e21682 (2020).","journal-title":"J. Clin. Oncol."},{"key":"13917_CR28","doi-asserted-by":"publisher","first-page":"e21577","DOI":"10.1200\/JCO.2020.38.15_suppl.e21577","volume":"38","author":"L Khaddour","year":"2020","unstructured":"Khaddour, L. et al. Immunotherapy in patients with advanced stage non-squamous NSCLC with activating genetic mutations: single institution retrospective study. J. Clin. Oncol. 38, e21577 (2020).","journal-title":"J. Clin. Oncol."},{"key":"13917_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.21037\/tlcr-24-17","volume":"13","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study. Transl. Lung Cancer Res. 13, 849 (2024).","journal-title":"Transl. Lung Cancer Res."},{"key":"13917_CR30","first-page":"100265","volume":"3","author":"D Fujimoto","year":"2022","unstructured":"Fujimoto, D. et al. A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC. JTO Clin. Res. Rep. 3, 100265 (2022).","journal-title":"JTO Clin. Res. Rep."},{"issue":"16_suppl","key":"13917_CR31","doi-asserted-by":"publisher","first-page":"e14635","DOI":"10.1200\/JCO.2024.42.16_suppl.e14635","volume":"42","author":"Z Lu","year":"2024","unstructured":"Lu, Z. et al. Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness. J. Clin. Oncol. 42 (16_suppl), e14635 (2024).","journal-title":"J. Clin. Oncol."},{"key":"13917_CR32","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"13917_CR33","unstructured":"Goodman, A. KEYNOTE-671 trial: perioperative pembrolizumab plus chemotherapy improves outcomes in stage II and III NSCLC. ASCO Highlights (2023)."},{"key":"13917_CR34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip, E. et al. Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 398, 1344\u20131357 (2021).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13917-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:14:21Z","timestamp":1757326461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13917-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13917"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13917-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28003"}}